Publikationen in Zusammenarbeit mit Forschern von Hospital General Universitario de Alicante (12)

2024

  1. Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib

    Annals of Hematology, Vol. 103, Núm. 11, pp. 4537-4544

  2. Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia

    Leukemia

2023

  1. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

    Cancers, Vol. 15, Núm. 4

2022

  1. Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH

    Clinical and Translational Oncology, Vol. 24, Núm. 5, pp. 770-783

  2. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270

  3. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

    Cancer, Vol. 128, Núm. 13, pp. 2441-2448

2021

  1. Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia

    British Journal of Haematology, Vol. 192, Núm. 6, pp. 988-996

  2. Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea

    Leukemia, Vol. 35, Núm. 2, pp. 623-627

  3. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

    Blood Cancer Journal

2020

  1. miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk

    Leukemia, Vol. 34, Núm. 10, pp. 2648-2659

2018

  1. Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients

    Blood Cancer Journal, Vol. 8, Núm. 10

2017

  1. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

    Haematologica, Vol. 102, Núm. 1, pp. 103-109